A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer
Carregando...
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCI LTD
Autores
FERRAROTTO, Renata
SHAH, Neeraj
COSTA, Frederico P.
OVERMAN, Michael J.
KOPETZ, Scott
Citação
EUROPEAN JOURNAL OF CANCER, v.48, n.6, p.820-826, 2012
Resumo
Background: A considerable number of metastatic colorectal cancer (mCRC) patients who progress on standard treatment with 5-fluorouracil (5FU), oxaliplatin, irinotecan and monoclonal antibodies, still have adequate performance status and desire further treatment. Mitomycin C (MMC) has been widely used in this context, and despite good tolerability, there are doubts regarding its true benefit. Methods: In order to assess the activity of MMC in the refractory mCRC setting, we retrospectively evaluated 109 heavily pre-treated patients who received MMC as single agent or in combination for mCRC at three different institutions in two countries. Results: Median patient's age was 54 years old, 57% were male and 94% had performance status ECOG 0 or 1. MMC was used in second line in 11%, third line in 38% and fourth line or beyond in 51% of patients. 58% received MMC combinations, mainly with capecitabine. Grade 3 or 4 toxicity was observed in 5% of patients and 6% required dose reductions. Median time to treatment failure (TTF) was 1.7 months with MMC and 3.6 months on the regimen prior to MMC, with a ratio between these TTF below 1 in 82% of patients. Median survival was only 4.5 months (95% confidence interval (CI) of 3.48-5.56). Conclusions: This retrospective data represent the largest reported series of unselected refractory mCRC patients treated with MMC. The median survival of 4.5 months is similar to the survival expected for best supportive care. This lack of activity strongly suggests that MMC should not be routinely used in refractory mCRC.
Palavras-chave
Mitomycin C, Metastatic colorectal cancer, Refractory setting
Referências
- Arkenau HT, 2009, ONCOLOGY-BASEL, V76, P151, DOI 10.1159/000195884
- Chester JD, 2000, ANN ONCOL, V11, P235, DOI 10.1023/A:1008356017611
- Chong G, 2005, BRIT J CANCER, V93, P510, DOI 10.1038/sj.bjc.6602733
- Fuchs CS, 2007, J CLIN ONCOL, V25, P4779, DOI 10.1200/JCO.2007.11.3357
- Gyldenkerne N, 2004, ACTA ONCOL, V43, P276, DOI 10.1080/02841860410028655
- Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
- Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
- Lim DH, 2005, CANCER CHEMOTH PHARM, V56, P10, DOI 10.1007/s00280-004-0963-2
- Wolmark N, 1998, J CLIN ONCOL, V16, P301
- MOERTEL CG, 1968, J AMER MED ASSOC, V204, P1045, DOI 10.1001/jama.204.12.1045
- Parkin DM, 2005, CA-CANCER J CLIN, V55, P74
- Peeters M, 2010, J CLIN ONCOL, V28, P4706, DOI 10.1200/JCO.2009.27.6055
- Price Timothy J, 2004, Clin Colorectal Cancer, V3, P235, DOI 10.3816/CCC.2004.n.004
- Rao S, 2004, BRIT J CANCER, V91, P839, DOI 10.1038/sj.bjc.6602039
- Rimassa L, 2006, TUMORI, V92, P285
- Rosati G, 2003, ANTICANCER RES, V23, P2981
- Ross P, 1997, ANN ONCOL, V8, P995, DOI 10.1023/A:1008263516099
- Rougier P, 1998, LANCET, V352, P1407, DOI 10.1016/S0140-6736(98)03085-2
- Rougier P, 2002, ANN ONCOL, V13, P1558, DOI 10.1093/annonc/mdf259
- Scheithauer W, 2002, CANCER INVEST, V20, P60, DOI 10.1081/CNV-120000367
- Tebbutt NC, 2010, J CLIN ONCOL, V28, P3191, DOI 10.1200/JCO.2009.27.7723
- Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
- Vaklavas C, 2011, CANCER-AM CANCER SOC, V117, P77, DOI 10.1002/cncr.25346
- Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
- Yamada Y, 2003, CANCER CHEMOTH PHARM, V52, P125, DOI 10.1007/s00280-003-0604-1